Equillium to Present at the JMP Securities Life Sciences Conference

Rhea-AI Summary

Equillium, a clinical-stage biotechnology company, announced its participation in the JMP Securities Life Sciences Conference on June 16-17, 2021. CEO Bruce Steel will overview itolizumab’s mechanism and ongoing clinical programs, focusing on the EQUATE study data for acute graft-versus-host disease, which will be revealed on June 11, 2021, at EHA. Attendees can access a live webcast of the presentation on the company’s website. Equillium develops itolizumab for severe autoimmune and inflammatory disorders, addressing critical medical needs.

LA JOLLA, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the JMP Securities Life Sciences Conference, a virtual investor event, taking place June 16 and 17, 2021.

Bruce Steel, Equillium’s chief executive officer, will provide a high-level overview of itolizumab’s mechanism of action and review each of the ongoing clinical programs, with a focus on topline data from the company’s EQUATE study in acute graft-versus-host disease, to be presented at EHA on Friday, June 11, 2021. Mr. Steel and other members of Equillium’s leadership team will be available for one-on-one meetings during the conference.

Date: Time: Location:

Wednesday, June 16, 2021 11:00 AM Eastern Time | 8:00 AM Pacific Time Virtual Webcast

A live webcast of the presentation will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/events-and-presentations. An archived replay will be available for 90 days.

About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.

For more information, visit www.equilliumbio.com.

Investor Contact
Michael Moore
Vice President, Investor Relations & Corporate Communications
619-302-4431
ir@equilliumbio.com

Media Contacts
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

 

FAQ

What is Equillium presenting at the JMP Securities Life Sciences Conference?

Equillium will present a high-level overview of itolizumab and ongoing clinical programs at the JMP Securities Life Sciences Conference.

When is Equillium's presentation scheduled?

Equillium's presentation is scheduled for June 16, 2021, at 11:00 AM Eastern Time.

What key data will be discussed in Equillium's presentation?

The presentation will focus on topline data from the EQUATE study concerning acute graft-versus-host disease.

Where can I watch Equillium's presentation live?

The live webcast of Equillium's presentation will be available on the company's website.

What does Equillium's itolizumab target?

Itolizumab is developed to treat severe autoimmune and inflammatory disorders, including acute graft-versus-host disease.